Chronic Wound and Tissue Defect Treatment with MIBRAR®

Chronic wounds and tissue defects are conditions that do not heal for more than 4-6 weeks despite standard treatment. They significantly reduce quality of life and can lead to serious complications, including amputation. MIBRAR® technology offers a fundamentally new approach — stimulating natural regeneration using autologous stem cells and growth factors.

Indications — Chronic Wounds

The MIBRAR® method is used for:

• Post-traumatic or post-surgical scar — pathological scarring
• Non-healing wound — wounds that don't heal for more than 6 weeks
• Diabetic foot — ulcers and tissue defects in diabetes
• Fistula in chronic inflammatory bowel disease — perianal fistulas in Crohn's disease
• Large tissue defect — including necrosis/tissue destruction
• Trophic ulcers — venous and arterial ulcers

Why Wounds Don't Heal

Normal wound healing involves sequential phases: inflammation, proliferation, remodeling. In chronic wounds, this process is disrupted:

• Chronic inflammation — elevated inflammatory cytokine levels
• Microcirculation impairment — tissue ischemia
• Infection — bacterial biofilm
• Growth factor deficiency — reduced regenerative potential
• Cell aging — reduced fibroblast and keratinocyte activity

MIBRAR® addresses several of these factors simultaneously by delivering a high concentration of growth factors and stem cells directly to the wound.

MIBRAR® Technology for Wounds

MIBRAR® uses ARK® — autologous regenerative concentrate:

• AHF® — plasma with growth factors (PDGF, VEGF, EGF, TGF-β), anti-inflammatory factors, CD34+ stem cells
• ALF® — mesenchymal stem cells from adipose tissue with high regenerative potential

The concentrate is injected into wound edges and bed, as well as into surrounding tissues to improve blood supply. Mesenchymal stem cells can differentiate into various cell types needed for tissue restoration.

Diabetic Foot

Diabetic foot syndrome is a severe diabetes complication affecting up to 25% of patients. Ulcers form due to neuropathy (loss of sensation), angiopathy (vessel damage), and impaired healing.

MIBRAR® advantages for diabetic foot:

• Stimulating angiogenesis — new blood vessel formation
• Reducing inflammation
• Accelerating epithelialization
• Reducing infection risk

In many cases, MIBRAR® allows avoiding amputation that was previously considered inevitable.

Trophic Ulcers

Trophic ulcers develop due to chronic venous insufficiency (venous ulcers) or peripheral arterial disease (arterial ulcers). They are characterized by prolonged course and tendency to recur.

MIBRAR® promotes ulcer healing by stimulating granulation tissue formation, improving microcirculation, and activating epithelialization. Stem cells provide long-term regenerative effect.

Fistulas

Fistulas — pathological passages between organs or between an organ and body surface — are particularly difficult to treat. Perianal fistulas in Crohn's disease often don't respond to standard therapy.

MIBRAR® is used for fistula treatment: ARK® is injected into fistula walls, stimulating closure. Mesenchymal stem cells have immunomodulatory properties and reduce inflammation characteristic of Crohn's disease.

Results and Prognosis

MIBRAR® treatment results for chronic wounds:

• Inflammation reduction — within first days after procedure
• Granulation tissue appearance — 1-2 weeks
• Wound size reduction — 2-4 weeks
• Complete epithelialization — 4-12 weeks depending on wound size

For large defects or long-standing wounds, repeated procedures may be required with 2-4 week intervals.